TPPU |
| Catalog No.GC15387 |
TPPU is a soluble epoxide hydrolase (sEH) inhibitor with IC50 values of 37 and 3.7 nM for monkey and human sEH.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1222780-33-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
TPPU is a soluble epoxide hydrolase (sEH) inhibitor with IC50 values of 37 and 3.7 nM for monkey and human sEH. TPPU has anti-inflammatory, analgesic, antiatherogenic and antihypertensive effects[1-2].
TPPU(1–10 μM; 48 h) reversed CORT-induced cell death in PC12 cells[3]. TPPU(0.1–10 μM; 24 h) protects tau from H2O2-induced hyperphosphorylation in HEK293/tau cells by regulating PI3K/AKT/GSK-3β pathway[4].
TPPU (i.p.; 10 mg/kg) treatment decreases serum dihydroxyeicosatrienoic acid (DHET) levels and serum IL-6 levels following burn injury, preventing DHET induced neutrophil depression in burn injury mice model [5]. TPPU(0-5 mg/L TPPU; delivered in drinking water; 1 week) increased exercise-induced effects on inhibiting cardiac enlargement and improving cardiac function by increasing EET levels in MI mice[6]. Pre-treatment with TPPU(0.1 mg/kg/d; i.g) attenuated seizures severity during status epilepticus (SE) and depressive behaviours during the period of epileptogenesis[7].
References:
[1]. Ulu A, Appt S, et,al. Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys. Br J Pharmacol. 2012 Mar;165(5):1401-12. doi: 10.1111/j.1476-5381.2011.01641.x. PMID: 21880036; PMCID: PMC3372725.
[2]. Li J, Wen Z, et,al. Soluble epoxide hydrolase inhibitor promotes the healing of oral ulcers. Clinics (Sao Paulo). 2023 May 4;78:100208. doi: 10.1016/j.clinsp.2023.100208. PMID: 37148830; PMCID: PMC10192938.
[3]. Wu Q, Song J, et,al. TPPU, a sEH Inhibitor, Attenuates Corticosterone-Induced PC12 Cell Injury by Modulation of BDNF-TrkB Pathway. J Mol Neurosci. 2019 Mar;67(3):364-372. doi: 10.1007/s12031-018-1230-z. Epub 2019 Jan 14. PMID: 30644034.
[4]. Yao ES, Tang Y, et,al. TPPU protects tau from H2O2-induced hyperphosphorylation in HEK293/tau cells by regulating PI3K/AKT/GSK-3β pathway. J Huazhong Univ Sci Technolog Med Sci. 2016 Dec;36(6):785-790. doi: 10.1007/s11596-016-1662-z. Epub 2016 Dec 7. PMID: 27924507.
[5]. Bergmann CB, Hammock BD, et,al. TPPU treatment of burned mice dampens inflammation and generation of bioactive DHET which impairs neutrophil function. Sci Rep. 2021 Aug 16;11(1):16555. doi: 10.1038/s41598-021-96014-2. PMID: 34400718; PMCID: PMC8368302.
[6]. Guo Y, Luo F, et,al. TPPU enhanced exercise-induced epoxyeicosatrienoic acid concentrations to exert cardioprotection in mice after myocardial infarction. J Cell Mol Med. 2018 Mar;22(3):1489-1500. doi: 10.1111/jcmm.13412. Epub 2017 Dec 19. PMID: 29265525; PMCID: PMC5824362.
[7]. Peng W, Shen Y et,al. TPPU Pre-Treatment Rescues Dendritic Spine Loss and Alleviates Depressive Behaviours during the Latent Period in the Lithium Chloride-Pilocarpine-Induced Status Epilepticus Rat Model. Brain Sci. 2021 Nov 5;11(11):1465. doi: 10.3390/brainsci11111465. PMID: 34827464; PMCID: PMC8615907.
|
Cell experiment [1]: |
|
|
Cell lines |
PC12 cells |
|
Preparation method |
PC12 cells were exposed to 200 μM CORT for 48 h and then with 1-10 μM TPPU. |
|
Reaction Conditions |
1-10 μM; 48 h |
|
Applications |
TPPU reversed CORT-induced cell death in PC12 cells. |
|
Animal experiment [2]: |
|
|
Animal models |
C57BL/6 mice |
|
Preparation method |
Myocardial infarction(MI) mouse model was established. After 1 week recovery, the surviving mice were randomly divided into four groups: non-myocardial infarction and non-exercise training (NMI NET), non-myocardial infarction with exercise training (NMI ET), myocardial infarction and non-exercise training (MI NET), and myocardial infarction with exercise training (MI ET).Mice in the ET groups underwent 4 weeks of exercise. To test the effect of TPPU on exercised mice, mice in the MI ET group were fed 0, 0.2, 1 or 5 mg/L TPPU for 1 week prior to the MI surgery and subsequent 4-week exercise programme. |
|
Dosage form |
0-5 mg/L TPPU; delivered in drinking water; 1 week |
|
Applications |
TPPU increased exercise-induced effects on inhibiting cardiac enlargement and improving cardiac function by increasing epoxyeicosatrienoic acid (EET) levels in MI mice. |
|
References: [1]. Wu Q, Song J,et,al. TPPU, a sEH Inhibitor, Attenuates Corticosterone-Induced PC12 Cell Injury by Modulation of BDNF-TrkB Pathway. J Mol Neurosci. 2019 Mar;67(3):364-372. doi: 10.1007/s12031-018-1230-z. Epub 2019 Jan 14. PMID: 30644034. [2]. Guo Y, Luo F et,al. TPPU enhanced exercise-induced epoxyeicosatrienoic acid concentrations to exert cardioprotection in mice after myocardial infarction. J Cell Mol Med. 2018 Mar;22(3):1489-1500. doi: 10.1111/jcmm.13412. Epub 2017 Dec 19. PMID: 29265525; PMCID: PMC5824362. |
|
| Cas No. | 1222780-33-7 | SDF | |
| Chemical Name | N-[1-(1-oxopropyl)-4-piperidinyl]-N’-[4-(trifluoromethoxy)phenyl)-urea | ||
| Canonical SMILES | CCC(N(CC1)CCC1NC(NC2=CC=C(OC(F)(F)F)C=C2)=O)=O | ||
| Formula | C16H20F3N3O3 | M.Wt | 359.3 |
| Solubility | ≤5mg/ml in ethanol;12.5mg/ml in DMSO;15mg/ml in dimethyl formamide | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7832 mL | 13.9159 mL | 27.8319 mL |
| 5 mM | 0.5566 mL | 2.7832 mL | 5.5664 mL |
| 10 mM | 0.2783 mL | 1.3916 mL | 2.7832 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *